3 results
To characterize the clearance pathways, the routes of excretion, total recovery of radioactivity, pacritinib and its major metabolites in healthy subjects following administration of a single oral dose of 400 mg [14C]pacritinibTo characterize the…
Primary• To determine the safety profile of oral topotecan in subjects with cancer andmildly moderately or severely impaired renal function (Groups C, D and E) compared to subjects with cancerwhose renal function is normal and who have received…
The primary objective is to assess treatment with rovalpituzumab tesirine improves overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who have first disease progression during or following front-line platinum based…